866-997-4948(US-Canada Toll Free)

Osteosarcoma - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 287 Pages

Osteosarcoma - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 16, 4, 16 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 4, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Osteosarcoma - Overview 7
Osteosarcoma - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Osteosarcoma - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 20
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Osteosarcoma - Companies Involved in Therapeutics Development 27
Advaxis Inc 27
Advenchen Laboratories LLC 27
Amgen Inc 28
AntiCancer Inc 28
Arrowhead Pharmaceuticals Inc 29
AVEO Pharmaceuticals Inc 29
Bayer AG 30
Bellicum Pharmaceuticals Inc 30
Boehringer Ingelheim GmbH 31
Bristol-Myers Squibb Company 31
Celldex Therapeutics Inc 32
Cellmid Ltd 32
CorMedix Inc 33
Daiichi Sankyo Company Ltd 33
Eisai Co Ltd 34
Eleison Pharmaceuticals LLC 34
Intezyne Technologies Inc 35
Ipsen SA 35
Isofol Medical AB 36
Johnson & Johnson 36
MacroGenics Inc 37
MD Biosciences GmbH 37
Merck & Co Inc 38
Merck KGaA 38
Novartis AG 39
Oncolys BioPharma Inc 39
Pfizer Inc 40
Teijin Pharma Ltd 40
Osteosarcoma - Drug Profiles 41
12-B80 - Drug Profile 41
3D-QM - Drug Profile 42
3D-QMS - Drug Profile 43
A-1R - Drug Profile 44
ADXS-HER2 - Drug Profile 46
aldoxorubicin hydrochloride - Drug Profile 50
AM-7209 - Drug Profile 68
apatinib - Drug Profile 69
AT-69 - Drug Profile 75
AU-101 - Drug Profile 76
AV-203 - Drug Profile 77
avelumab - Drug Profile 80
axitinib - Drug Profile 91
BMTP-11 - Drug Profile 97
CAB-102 - Drug Profile 99
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 101
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 103
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 104
Celyvir - Drug Profile 105
cisplatin SR - Drug Profile 106
daunorubicin hydrochloride - Drug Profile 108
dihydroartemisinin - Drug Profile 109
DS-5272 - Drug Profile 110
enoblituzumab - Drug Profile 111
everolimus - Drug Profile 114
glembatumumab vedotin - Drug Profile 126
ipilimumab + nivolumab - Drug Profile 132
irinotecan hydrochloride - Drug Profile 140
JNJ-7107 - Drug Profile 152
lenvatinib mesylate - Drug Profile 155
ligerin - Drug Profile 169
MD-401A - Drug Profile 170
Minnelide - Drug Profile 171
Modufolin - Drug Profile 173
Monoclonal Antibody for Osteosarcoma - Drug Profile 176
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 177
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 178
OBP-702 - Drug Profile 180
Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile 181
pazopanib hydrochloride - Drug Profile 182
pembrolizumab - Drug Profile 190
radium Ra 223 dichloride - Drug Profile 251
RSF-101 - Drug Profile 260
SEN-461 - Drug Profile 262
sirolimus albumin-bound - Drug Profile 263
Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile 265
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 266
Small Molecules to Inhibit MDM2 for Osteosarcoma - Drug Profile 267
taurolidine - Drug Profile 268
Vaccine for Osteosarcoma - Drug Profile 269
VIMO-001 - Drug Profile 270
Osteosarcoma - Dormant Projects 271
Osteosarcoma - Discontinued Products 273
Osteosarcoma - Product Development Milestones 274
Featured News & Press Releases 274
Appendix 282
Methodology 282
Coverage 282
Secondary Research 282
Primary Research 282
Expert Panel Validation 282
Contact Us 282
Disclaimer 283

List of Tables
Number of Products under Development for Osteosarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Osteosarcoma - Pipeline by Advaxis Inc, H2 2017
Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2017
Osteosarcoma - Pipeline by Amgen Inc, H2 2017
Osteosarcoma - Pipeline by AntiCancer Inc, H2 2017
Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2017
Osteosarcoma - Pipeline by Bayer AG, H2 2017
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017
Osteosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H2 2017
Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H2 2017
Osteosarcoma - Pipeline by Cellmid Ltd, H2 2017
Osteosarcoma - Pipeline by CorMedix Inc, H2 2017
Osteosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Osteosarcoma - Pipeline by Eisai Co Ltd, H2 2017
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2017
Osteosarcoma - Pipeline by Intezyne Technologies Inc, H2 2017
Osteosarcoma - Pipeline by Ipsen SA, H2 2017
Osteosarcoma - Pipeline by Isofol Medical AB, H2 2017
Osteosarcoma - Pipeline by Johnson & Johnson, H2 2017
Osteosarcoma - Pipeline by MacroGenics Inc, H2 2017
Osteosarcoma - Pipeline by MD Biosciences GmbH, H2 2017
Osteosarcoma - Pipeline by Merck & Co Inc, H2 2017
Osteosarcoma - Pipeline by Merck KGaA, H2 2017
Osteosarcoma - Pipeline by Novartis AG, H2 2017
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2017
Osteosarcoma - Pipeline by Pfizer Inc, H2 2017
Osteosarcoma - Pipeline by Teijin Pharma Ltd, H2 2017
Osteosarcoma - Dormant Projects, H2 2017
Osteosarcoma - Dormant Projects, H2 2017 (Contd..1), H2 2017
Osteosarcoma - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Osteosarcoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *